🧭 Biology, monetised
Health & Longevity.
GLP-1s reshaping food, pharma, and insurance; digital health; personalised medicine; and the commercial infrastructure emerging around longevity science.
The GLP-1 Economy
🔥 BreakoutOzempic, Wegovy, Mounjaro, Zepbound are reshaping entire industries beyond obesity treatment — food companies pivoting portfolios, insurance reserving, airlines measuring passenger weight changes, knee-replacement surgery pipelines reforecasting.
2 sources · updated 2026-04-26 →
Personalised Medicine Commercialisation
📈 RisingCAR-T therapies, tumour-agnostic oncology, pharmacogenomics-guided prescribing are all moving into broader clinical use. Reimbursement frameworks (outcomes-based contracts) evolving in parallel.
1 source · updated 2026-04-26 →
Digital Health Platform Maturation
➤ SteadyPost-COVID telehealth shake-out mostly complete. Virtual-first primary care, asynchronous mental health, and chronic-care management reaching clinical + economic credibility. Teladoc, Hims, Ro, Cerebral remain major actors.
1 source · updated 2026-04-26 →
Longevity Science — Commercial Layer
📈 RisingSenolytic research, rapamycin analogues, NAD+ precursors, and epigenetic reprogramming all have preliminary clinical results. $5B+ of capital deployed to Altos, Retro, Rejuvenate, Loyal. Commercial products on-shelf remain mostly unvalidated.
1 source · updated 2026-04-26 →
Workplace Mental Health
➤ SteadyMental-health benefits spend has become a standard enterprise HR line. Lyra, Spring Health, Modern Health continuing enterprise growth; Unmind, Calm for Business maintaining share. Parity laws in multiple US states.
1 source · updated 2026-04-26 →